Joinn Laboratories(China)Co (603127) - Total Liabilities
Based on the latest financial reports, Joinn Laboratories(China)Co (603127) has total liabilities worth CN¥1.48 Billion CNY (≈ $216.53 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Joinn Laboratories(China)Co (603127) asset resilience to evaluate the company's liquid asset resilience ratio.
Joinn Laboratories(China)Co - Total Liabilities Trend (2012–2025)
This chart illustrates how Joinn Laboratories(China)Co's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Joinn Laboratories(China)Co.
Joinn Laboratories(China)Co Competitors by Total Liabilities
The table below lists competitors of Joinn Laboratories(China)Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JK Cement Limited
NSE:JKCEMENT
|
India | Rs-70.90 Billion |
|
Seazen Holdings Co Ltd
SHG:601155
|
China | CN¥179.67 Billion |
|
Huber+suhner AG
SW:HUBN
|
Switzerland | CHF191.91 Million |
|
Integer Holdings Corp
NYSE:ITGR
|
USA | $1.70 Billion |
|
OPENLANE, Inc.
NYSE:OPLN
|
USA | $3.44 Billion |
|
Magnolia Oil & Gas Corp
NYSE:MGY
|
USA | $917.17 Million |
|
Patterson-UTI Energy Inc
NASDAQ:PTEN
|
USA | $2.27 Billion |
|
Ningbo Joyson Electronic Corp
SHG:600699
|
China | CN¥45.99 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Joinn Laboratories(China)Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Joinn Laboratories(China)Co to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Joinn Laboratories(China)Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Joinn Laboratories(China)Co (2012–2025)
The table below shows the annual total liabilities of Joinn Laboratories(China)Co from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.36 Billion ≈ $198.51 Million |
+3.01% |
| 2024-12-31 | CN¥1.32 Billion ≈ $192.71 Million |
-24.58% |
| 2023-12-31 | CN¥1.75 Billion ≈ $255.51 Million |
-19.66% |
| 2022-12-31 | CN¥2.17 Billion ≈ $318.03 Million |
+56.06% |
| 2021-12-31 | CN¥1.39 Billion ≈ $203.79 Million |
+57.60% |
| 2020-12-31 | CN¥883.66 Million ≈ $129.31 Million |
+49.63% |
| 2019-12-31 | CN¥590.57 Million ≈ $86.42 Million |
+20.55% |
| 2018-12-31 | CN¥489.89 Million ≈ $71.69 Million |
+27.88% |
| 2017-12-31 | CN¥383.08 Million ≈ $56.06 Million |
+13.72% |
| 2016-12-31 | CN¥336.88 Million ≈ $49.30 Million |
+23.11% |
| 2015-12-31 | CN¥273.64 Million ≈ $40.04 Million |
-6.49% |
| 2014-12-31 | CN¥292.63 Million ≈ $42.82 Million |
+13.33% |
| 2013-12-31 | CN¥258.21 Million ≈ $37.78 Million |
-8.04% |
| 2012-12-31 | CN¥280.79 Million ≈ $41.09 Million |
-- |
About Joinn Laboratories(China)Co
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics… Read more